Adaptive Diagnostics Aldatu focuses on PANDAA adaptive PCR diagnostics for diverse pathogens, ideal for expanding robust infectious disease testing in low- and middle-income regions where sales channels for molecular diagnostics and point-of-care solutions are growing.

NIH Backing Significant non-dilutive funding from NIH totaling over $20 million and recent SBIR grants indicate strong credibility and potential funding avenues for customer-funded deployments, government programs, and co-development opportunities.

Quality & Compliance ISO 13485 certified quality management system supports credibility with healthcare providers, labs, and public health institutions, easing procurement and contract discussions for validated diagnostics.

Global Health Focus Emphasis on epidemic preparedness and diagnostics in resource-limited settings aligns with international aid programs, NGO partnerships, and multinational health initiatives seeking robust testing across diverse genetic landscapes.

Growth Levers Current revenue range (1–10M) and lean headcount suggest potential for strategic partnerships, licensing, or manufacturing collaborations to scale PANDAA-based offerings and accelerate market penetration in high-demand regions.